ESMO 2024

Avelumab first-line maintenance in advanced urothelial carcinoma: conditional survival and long term safety in patients treated for ≥1 or ≥2 years in JAVELIN Bladder 100

Grivas P, et al. 

Insights into second-line systemic treatment selection in patients with metastatic urothelial carcinoma: results of a retrospective observational study in Germany

Niegisch G, et al. 

Subgroup analyses of patients with advanced urothelial carcinoma who had long-term progression-free survival or overall survival with avelumab first line maintenance in the AVENANCE real-world study

Barthélémy P, et al. 

Primary analysis of post-marketing surveillance data for avelumab maintenance therapy in patients with curatively unresectable urothelial carcinoma in Japan

Kikuchi E, et al. 

Avelumab in metastatic Merkel cell carcinoma: conditional survival and long-term safety in patients treated for ≥1 or ≥2 years in JAVELIN Merkel 200

Lebbé C, et al. 

Avelumab + axitinib vs sunitinib in advanced renal cell carcinoma (aRCC): final analysis of patient-reported outcomes (PROs) and quality-adjusted time without symptoms or toxicity (Q-TWIST)

Venugopal B, et al. 

M9140, an anti-CEACAM5 antibody-drug conjugate (ADC), in patients with metastatic colorectal cancer (mCRC): updated results from a Phase 1 tiral

Boni V, et al. 

Translational, PK, and PD analyses of tuvusertib + niraparib in a Phase I open-label multicenter dose-escalation study in patients with advanced solid tumors (DDRiver Solid Tumors 301)

Tolcher AW, et al. 

Real-world treatment patterns and survival outcomes associated with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN): a German claims data analysis

Kuhnt T, et al.